IBIS-II DCIS
- Researchers are looking to recruit 4,000 women who have passed the menopause and have been diagnosed with and had surgery to remove hormone receptor positive DCIS.
- The study is investigating which is more effective, anastrozole or tamoxifen, at preventing new cancers, both in the breast affected by DCIS and in the opposite (contralateral) breast.
- Women on the trial will take two tablets every day for five years. One of the tablets contains either anastrozole or tamoxifen and the other tablet is a dummy pill (placebo).
- The DCIS trial will be recruiting women until December 2010. The first set of results is expected in 2012.
- The DCIS trial is part of a large international breast cancer intervention study called IBIS-II which is supported by Cancer Research UK and sponsored by Queen Mary, University of London.
